MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Venus Concept Operating Income 2011-2026 | VERO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Venus Concept
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -27.2 M | -28.3 M | -34.9 M | -14.8 M | -67.9 M | -30.3 M | -3.37 M | -17.3 M | -18.9 M | -20.5 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.37 M | -67.9 M | -26.3 M |
Quarterly Operating Income Venus Concept
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.5 M | -9.04 M | -9.53 M | - | -7.16 M | -5.6 M | -7.76 M | - | -6.76 M | -5.76 M | -8.16 M | - | -11.4 M | -7.13 M | -7.44 M | - | -5.39 M | 1.53 M | -6.84 M | - | -5.29 M | -8.81 M | -43.6 M | - | -6.56 M | -3.95 M | -1.87 M | - | -6.44 M | -5.17 M | -7.04 M | - | -4.61 M | -4.44 M | -4.42 M | - | -5.33 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.53 M | -43.6 M | -7.62 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
-9.34 M | $ 2.18 | 1.87 % | $ 3.4 M |  USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 10.73 | 2.98 % | $ 1.45 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 4.14 | 5.88 % | $ 876 M | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 8.52 | 1.67 % | $ 612 M |  Israel |
 |
CONMED Corporation
CNMD
|
103 M | $ 36.66 | -2.0 % | $ 1.14 B | USA |
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 12.71 | 0.87 % | $ 1.91 B | USA |
 |
Cytosorbents Corporation
CTSO
|
-16.8 M | $ 0.69 | 6.15 % | $ 37.6 M | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 4.16 | 4.95 % | $ 155 M |  France |
 |
Boston Scientific Corporation
BSX
|
3.61 B | $ 71.56 | 2.54 % | $ 106 B | USA |
 |
Establishment Labs Holdings
ESTA
|
-39 M | $ 65.03 | 2.43 % | $ 1.93 B |  Costa-rica |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
InMode Ltd.
INMD
|
85.4 M | $ 13.64 | 1.56 % | $ 882 M | Israel |
 |
ClearPoint Neuro
CLPT
|
-19.7 M | $ 11.14 | 1.0 % | $ 301 M | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.34 | 0.77 % | $ 21.6 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.42 | - | $ 121 M | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.19 | -0.23 % | $ 1.33 M | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 61.86 | 0.7 % | $ 3.37 B |  Britain |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
MiMedx Group
MDXG
|
63.9 M | $ 4.5 | 1.93 % | $ 665 M | USA |
 |
Abbott Laboratories
ABT
|
8.05 B | $ 111.24 | 1.17 % | $ 194 B | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 9.82 | 0.05 % | $ 352 M | USA |
 |
Bio-Rad Laboratories
BIO
|
269 M | $ 265.0 | 1.44 % | $ 7.48 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-56.7 M | $ 2.56 | -1.16 % | $ 150 M | Israel |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 9.27 | 2.89 % | $ 714 M | USA |
 |
AxoGen
AXGN
|
-7.85 M | $ 32.87 | 0.08 % | $ 1.51 B | USA |
 |
Align Technology
ALGN
|
608 M | $ 175.45 | 3.54 % | $ 13.1 B | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 33.48 | 2.18 % | $ 4.99 K | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
-6.45 M | $ 3.86 | 5.07 % | $ 159 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 17.24 | 0.76 % | $ 404 M | USA |